Amgen director granted 665 shares in stock award

ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.

Amgen director Omar Ishrak received a stock grant of 665 shares of common stock as compensation. The award was made as Restricted Stock Units under Amgen’s 2009 director incentive program and vested immediately, with payment in common shares on a one-to-one basis.

After this grant, Ishrak directly holds a total of 7,358.7361 Amgen common shares. Footnotes indicate the total includes 418 dividend equivalents credited to his unvested RSUs, which will also be settled in shares according to their vesting schedule.

Insights

Equity compensation analyst

Routine director equity grant increases Amgen insider holdings modestly.

Amgen granted director Omar Ishrak 665 shares of common stock via immediately vested Restricted Stock Units under its 2009 director incentive program. This is a standard form of non-cash board compensation rather than an open-market purchase or sale.

Following the grant, Ishrak holds 7,358.7361 common shares directly, including 418 dividend equivalent units tied to unvested RSUs. The filing shows no derivative exercises or sales, so this is a straightforward increase in his equity exposure through the company’s long-standing incentive plan.

Insider Trade Summary

Grant/Award: 665 shares

Grant/Award 1 txn

Insider ISHRAK OMAR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	665	$0.00	$0.00

Holdings After Transaction: Common Stock — 7,358.7361 shares (Direct)

Footnotes (2)

1. F1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
2. F2. These shares include 418 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

Shares granted: 665 shares Grant price: $0.00 per share Shares after transaction: 7,358.7361 shares +2 more

5 metrics

Shares granted 665 shares Restricted Stock Unit grant of common stock on May 19, 2026

Grant price $0.00 per share Equity compensation award, not a market purchase

Shares after transaction 7,358.7361 shares Total direct Amgen common stock holdings following the RSU grant

Dividend equivalents 418 DEs Dividend equivalents tied to unvested RSUs, payable in shares

Transactions acquiring 1 transaction Single grant, award, or other acquisition reported in summary

Key Terms

Restricted Stock Units (RSUs), dividend equivalents (DEs), dividend reinvestment plan, Equity Incentive Plan, +1 more

5 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

dividend equivalents (DEs) financial

"These shares include 418 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

dividend reinvestment plan financial

"418 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Equity Incentive Plan financial

"under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

director incentive program financial

"granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) director Omar Ishrak report in this Form 4?

Omar Ishrak reported receiving 665 shares of Amgen common stock as a grant of Restricted Stock Units that vested immediately. This award is part of Amgen’s director incentive program and represents routine equity-based board compensation rather than an open-market stock purchase.

How many Amgen (AMGN) shares does Omar Ishrak hold after this transaction?

After the grant, Omar Ishrak directly holds 7,358.7361 shares of Amgen common stock. This total includes 418 dividend equivalents credited to his unvested Restricted Stock Units, which will be paid out in shares according to their vesting schedule, plus cash for any fractional share remainder.

Was Omar Ishrak’s Amgen (AMGN) Form 4 transaction a stock purchase or sale?

The Form 4 shows an acquisition through a grant, not a market trade. Ishrak received 665 shares via a Restricted Stock Unit award at a price per share of $0.00, reflecting compensation. The filing reports no open-market purchases or sales of Amgen common stock in this transaction.

What are the terms of the Restricted Stock Units granted to Omar Ishrak at Amgen (AMGN)?

The Restricted Stock Units were granted under Amgen’s 2009 Director Incentive Program and vested immediately. Vested RSUs are paid in Amgen common shares on a one-to-one basis, and directors may defer payment, in which case shares are delivered according to their elected deferral schedule.

What are dividend equivalents (DEs) mentioned in Omar Ishrak’s Amgen (AMGN) Form 4?

The filing notes 418 dividend equivalents, or DEs, credited under Amgen’s equity plan and tied to unvested RSUs. These DEs are paid out in Amgen common shares on a one-to-one basis following the RSU vesting schedule, plus a cash payment for any remaining fractional share amount.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 07:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ISHRAK OMAR

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		665	A	$0	7,358.7361(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

2. These shares include 418 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ S. Omar Ishrak	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)